Proteomics Characterization of Haptoglobin Alpha-2 Subunit in Non-Small Cell Lung Cancer Serum and Various Human Materials

Haou-Tzong Ma1, Supawadee Sriyam1,2, Supachok Sinchaikul1, Hsien-Yu Tsai1, Suree Phutrakul2 and Shui-Tein Chen1,3*

1Institute of Biological Chemistry, Academia Sinica, Taipei, 11529, Taiwan
2Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai, 50200, Thailand
3Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, 10617, Taiwan

Abstract

Non-small cell lung cancer (NSCLC) is detected in all lung cancer patients and the serum samples as potential source are often used as a potential source for early diagnosis. In this study, we used the proteomic approaches combining 2-DE, 2-D DIGE and mass spectrometry to identify the potential serum biomarkers in NSCLC serum samples, and compare the result to normal serum samples. The haptoglobin alpha 2 subunit (HAP2) is one of the proteins we are interested in and showed the overexpression level in NSCLC serum amongst the NSCLC subtypes. The identity of HAP2 was confirmed by LC-MS/MS and NH2-terminal amino acid sequencing analyses, while the high expression level of HAP2 in NSCLC serum samples was validated using co-immunoprecipitation and western blotting. Interestingly, the high expression of HAP2 has specificity in human serum samples, but non-specific expression in lung cancer tissues and is not observed in lung cancer cell lines except HepG2 hepatocellular carcinoma cell line. This indicates that HAP2 is not produced from lung tissues and/or cells, but may be secreted from the liver. In addition, HAP2 isoforms and its post-translational modifications (PTMs) could be detected by various staining methods such as phosphoprotein, glycoprotein stains and FITC-labeled lectins stain. The different carbohydrate specificities of HAP2 isoforms in NSCLC serum samples, especially sialyl Lewis x, was observed and may correlate to the development or metastasis of lung cancer. We suggest that HAP2 may become a potentially useful serum biomarker for early diagnostic and therapeutic applications.

Keywords: Lung cancer; Proteomics; Human Serum; Biomarker; Haptoglobin

Abbreviations: CAN: Acetonitrile; CHCA: α-Cyano-4-Hydroxycinnamic Acid; 2-DE: Two-Dimensional Electrophoresis; 2-D DIGE: Two-Dimensional Differential in-gel Electrophoresis; FITC: Fluorescein Isothiocyanate; HAP2: Haptoglobin Alpha-2 subunit; MS: Mass Spectrometry; NSCLC: Non-Small Cell Lung Cancer; PTMs: Post-translational Modifications; TFA: Trifluoroacetic Acid

Introduction

Lung cancer is the cause of more cancer-related mortality in the world today for both men and women than any other cancer. There are many reports showing that the incidence of lung cancer has increased significantly among Asian with the first or second order of cancer death during the past few decades [1-3]. Lung cancer is divided into two main types; Small Cell Lung Cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is the common type of lung cancer, accounting for approximately 80% of all lung cancer types. There are three main subtypes based on the kind of cancer cells; adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Regardless of the subtype, the five-year survival rate for lung cancer is less than 15% from the time of diagnosis [4,5]. Although more than half of lung cancers are diagnosed at a late stage, when cure is unlikely, the survival of patients diagnosed with stage I lung cancer is also surprisingly low. Thus, there is a great need to understand the molecular and biological alterations of lung cancer that lead to a poor diagnosis and to use this information to improve diagnosis, patient management and therapy.

Over the past two decades, significant progress has been made toward understanding the molecular pathogenesis of human lung cancer by the identification and characterization of various cancer-related genes and/or proteins that are genetically or epigenetically altered in human lung cancer. Numerous protein markers have been elucidated in human serum, urine, seminal fluid and histological specimens that exhibit varying capacities to detect lung cancer and predict disease cause. The human serum and plasma circulated in the human system provide a wealth of diagnostic tools and are mostly used by proteomics for detecting researchers and therapeutic monitoring from a clinical viewpoint. Therefore, many researches have attempted to identify all the proteins in serum and/or plasma and reduce the complexity of the proteome by using proteomic analysis of human blood serum [6-8]. However, to date, few of these markers have been adequately validated for clinical use, and many more remain unidentified.

Using proteomic approaches are particularly promising for identifying protein markers from the amount of blood serum. The objective of this study was therefore to identify the novel serum biomarkers from NSCLC patients using proteomic approaches, i.e. 2-DE, 2-D DIGE and mass spectrometry. The Haptoglobin alpha-2 subunit (HAP2), which is the up-regulated protein in NSCLC serum, is our target protein and is used to validate the expression level in various human materials for answering the question of HAP2 production from lung cancer tissues and/or cells. Moreover, the sequential staining methods were used to characterize the post-translational modifications (PTMs) of HAP2, in which the FITC-labeled lectin

*Corresponding author: Shui-Tein Chen, Room 709, Institute of Biological Chemistry, Academy Sinica 128, Academia Road Sec. 2, Nankang, Taipei 115, Taiwan, Tel: +886-2-2785-5981 ext. 7141; Fax: +886-2-2788-347; E-mail: bchen@gate.sinica.edu.tw

Received August 30, 2013; Accepted September 25, 2013; Published September 28, 2013

Citation: Ma HT, Sryiam S, Sinchaikul S, Tsai HY, Phutrakul S, et al. (2013) Proteomics Characterization of Haptoglobin Alpha-2 Subunit in Non-Small Cell Lung Cancer Serum and Various Human Materials. J Proteomics Bioinform 6: 187-196. doi:10.4172/jpb.1000280

Copyright: © 2013 Ma HT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
staining could detect the specific carbohydrate moieties in HAP2. The co-immunoprecipitation against the sialyl Lewis x antibody was also used to investigate the modification of sialyl Lewis x in HAP2. Therefore, we initiated the present work to elucidate the potential biomarkers in NSCLC serum, especially HAP2, the characterization of PTMs by HAP2, and the source of HAP2.

**Experimental Procedures**

**Materials**

Human serum samples from lung cancer patients and healthy donors were provided from Lampang Regional Cancer Center, Lampang, Thailand. Bio-Rad Protein assay was purchased from Bio-Rad (Hercules, CA, USA). Immobiline™ Dry strips length 18 cm; pH 3-10NL and 4-7L; IPG buffers (pH 3-10NL and 4-7L) and CyDye maleimide fluoros (Cy3/Cy5) were purchased from GE Healthcare (Uppsala, Sweden). Acrylamide/Bis-acrylamide (37.5:1) solution, Tris, CHAPS and glycine were purchased from BioShop (Burlington, ON, Canada). Dithioerythritol (DTE) was purchased from AppliChem (Darmstadt, Germany). Iodoacetamide was purchased from Fluka (Buchs, Switzerland). Sequencing grade modified trypsin was purchased from Promega (Madison, WI, USA). SYPRO® Ruby, Pro-Q® Diamond phosphoprotein and Pro-Q® Emerald 488 glycoprotein gel stains were purchased from Molecular Probes (Eugene, OR, USA). Polyvinylidene difluoride (PVDF) membrane was purchased from Millipore (Billerica, MA, USA). Polyclonal antibody rabbit anti-human haptoglobin was purchased from Dako cytomation (Glostrup, Denmark). Monoclonal antibody mouse anti-sialyl Lewis x was purchased from Chemicon International Inc. (Temecula, CA, USA). Naphthol blue black, urea, thiourea and anti-rabbit horseradish peroxidase (HRP, secondary antibody) were purchased from Sigma (St. Louis, MO, U.S.A.). FITC- labeled lectins were obtained from Vector Laboratories (Burlingame, CA, USA). All buffers were prepared with Milli-Q water (Millipore, Bedford, MA, USA).

**Human serum specimens**

All of samples were obtained during diagnosis of eighteen NSCLC patients, all of whom were divided into three groups: adenocarcinoma (eight samples), squamous cell carcinoma (five samples) and unknown type (five samples) according to histological cell types. The ages of the patients ranged from 41 to 75 years (median age, 57 years). The serum samples were obtained from blood specimens that were allowed to clot for 30 min to 1 h at room temperature and then centrifuged at 3000×g for 30 min. The supernatants of the serum samples were collected, for 12000×g for 20 min, the sample solutions were applied onto IPG strip (Immobiline DryStrip, 18 cm, pH 4-7 or pH 3-10 NL, GE Healthcare). IPGphor IEF (GE Healthcare) was performed under the following conditions: gel rehydration was carried out for 14 h at 50 V and run in the programmed setting for a total of 65 kVh. After IEF, the IPG strips were equilibrated in equilibration buffer (50 mM Tris-HCl, pH 8.8, 6 M urea, 30% v/v glycerol, 2% w/v DTE and a trace of bromophenol blue) for 15 min and then subsequently alkylated in the same equilibration buffer, but with 2.5% w/v iodoacetamide replacing DTE for 15 min. The IPG strips were placed on top of the 10-18% linear gradient polyacrylamide gel (18×18 cm) and covered with 0.5% agarose. The second-dimensional separation was carried out at 45 mA per gel at 15°C until the bromophenol blue dye reached the bottom of the gel. At the end of each run, the 2-D gels were stained with SYPRO® Ruby gel staining and scanned using a Typhoon 9200 scanner (GE Healthcare). In addition, the 2-D gel images were exported to the image analysis software program, using ImageMaster™ 2D Platinum software version 5.0 (GE Healthcare).

**2-D DIGE analysis**

Each of the normal and lung cancer serum proteins was minimally labeled with CyDye maleimide (Cy3, Cy5) according to the manufacturer’s instructions (GE Healthcare). Before the first dimension isoelectric focusing (IEF), an aliquot from each of the CyDyed labeled samples was mixed together and added to rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 65 mM DTE, and 0.5% IPG buffer pH 4-7). The mixed sample was applied onto IPG strip (Immobiline DryStrip, 18 cm, pH 4-7, GE Healthcare) and the IEF was performed using an Ettan IPGphor (GE Healthcare), as described above. Following equilibration, the IPG strip was placed on top of a 10-18% polyacrylamide gel. The second-dimensional separation was carried out at 45 mA per gel at 15°C until the bromophenol blue dye front reached the bottom of the gel. At the end of each run, the 2-D gel was stained using a Typhoon 9200 laser scanner (GE Healthcare) with two wavelengths at an emission filter of 580 nm (Cy3) and 670 nm (Cy5).

**In-Gel tryptic digestion**

Protein spots were manually excised from the gels and transferred to 500 µl siliconized Eppendorfs. The gel pieces were washed twice with 200 µl of 50% ACN/25 mM ammonium bicarbonate buffer, pH 8.5, for 15 min each. The gel pieces were then washed once with 200 ml of 100% ACN and dried using a Speed-Vacuum concentrator. Dried gel pieces were swollen in 20 µl of 25 mM ammonium bicarbonate containing 0.1 mg trypsins. Gel pieces were then crushed with a siliconized blue stick and incubated at 37°C for at least 16 h. Peptides were subsequently extracted twice with 50 µl of 50% ACN/5% TFA, then the extracted solutions were combined and dried using a SpeedVac concentrator. The peptides were eluted with 5 µl of 75% ACN/0.1% formic acid.

**MALDI-TOF MS and MS/MS analysis**

The samples were premixed in a ratio of 1:1 with matrix solution (5 mg/ml CHCA in 50% ACN, 0.1% v/v TFA and 2% w/v ammonium citrate) and spotted onto the 96-wells format MALDI sample stage. Data was directed acquired on the Q-TOF Ultima™ MALDI instrument (M@LDI®; Micromass, Manchester, UK) which was fully automated with a predefined probe motion pattern and peak intensity threshold for switching over from MS survey scanning to MS/MS, and from one MS/MS to another. Within each well, parent ions that met the predefined criteria (any peak within the m/z 800–3000 range with intensity above 10 count ± include/exclude list) were selected from the most intense peak for CID MS/MS using argon as the collision gas and a mass dependent ± 5V rolling collision energy until the end of the...
probe pattern was reached (all details are available at http://proteome.sinica.edu.tw). The MASCOT MS ion search program (http://www.matrixscience.com) was used for protein searching. Search parameters allowing for oxidation of methionine, carboxamidomethylation of cysteine and one missed trypsin cleavage were selected for searching the Swiss-Prot database. Protein identification was repeated at least once using spots from different gels. In addition, the identified proteins were searched for the description based on the Swiss-Prot and NCBI protein databases.

**LC-MS/MS**

The tryptic digested peptides were analyzed by 1-D LC-nanoESI MS/MS. The 1-D LC-nano ESI-MS/MS analysis was performed on an integrated nanoLC/MS/MS system (Micromass) comprising of a three-pump Micromass/Waters CapLC® system with an autosampler, a stream selection module configured for precolumn plus analytical capillary column, and a Micromass Q-Tof Ultima™ API mass spectrometer fitted with a nano-LC sprayer, operated under MassLynx® 4.0 control. Injected samples were first trapped and desalted isocratically on an LC-Packsing PepMap™ C18 μ-Precolumn™ Cartridge (5 µm, 300 µm id×5 mm; Dionex, Sunnyvale, CA, USA) for 2 min with 0.1% formic acid delivered by the auxiliary pump at 30 µL/min after which the peptides were eluted off from the precolumn and separated on an analytical C18 capillary column (15 cm×5 µm id, packed with 5 µm, Zorbax 300 SB C18 particles; Micro-Tech Scientific, Vista, CA, USA) connected inline to the mass spectrometer, at 300 nl/min using a 40 min fast gradient of 5% to 80% acetonitrile in 0.1% formic acid. The peptide fragment fingerprint data were subjected to Swiss-Prot protein databases.

**Phosphoprotein and glycoprotein staining**

Phosphoprotein and glycoprotein staining were performed using Pro-Q™ Diamond phosphoprotein gel stain and Pro-Q® Emerald 488 glycoprotein gel stain, respectively, according to the manufacturer’s instruction (Molecular Probes). The 2-D gel images of the stained gels were scanned using a Typhoon 9200 laser scanner (GE Healthcare). The gels were post-stained with SYPRO Ruby to detect the total amount of protein on the gels.

**NH₂-terminal analysis**

The protein spots on the 2-DE gel were electrotransferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was stained with 0.2% Naphthol blue black, and the protein band was excised to determine the NH₂-terminal amino acid sequence. NH₂-terminal sequencing was performed by Edman degradation using an Applied Biosystems Model 492 precise sequencer (Applied Biosystems, Weiterstadt, Germany). The protein search of NH₂-terminal sequences was carried out using BLAST software from protein database at the ExPASy website (http://au.expasy.org/tools/#similarity).

**Western blot analysis**

Serum proteins were separated by 12.5% SDS-PAGE and electrotransferred to PVDF membrane. The membranes were blocked for 2 h with 5% skim milk and 0.1% Tween-20 in PBS, followed by incubation with the primary antibody of polyclonal rabbit anti-human haptoglobin (1:40,000 dilution) for 2 h at room temperature. After washing three times with PBS-0.1% Tween-20, the primary antibody was detected with the secondary antibody of anti-rabbit horseradish peroxidase (HRP; 1:5,000 dilution) for 1 h at room temperature, and the signals were developed by enhanced chemiluminescence western blotting detection system (ECL™ kit; GE Healthcare).

**Co-Immunoprecipitation**

Two primary antibodies were used in this experiment, olyclonal antibody rabbit anti-human haptoglobin and monoclonal antibody mouse anti-sialyl Lewis x. Five hundred micrograms of total protein from the serum samples were incubated with appropriate amounts of primary antibody at room temperature for 2 h. The sample mixture was incubated overnight with protein A-Sepharose (15 µl, GE Healthcare) and incubated at room temperature for 2 h with rocking. Immunoprecipitates were pelleted by centrifugation and washed three times with washing buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40 (NP-40), 1 mM EDTA (pH 8.0), 0.25% gelatin and 0.02% sodium azide). Captured proteins were eluted by boiling the beads in loading sample buffer for 5 min at 100°C. Samples were subjected to SDS-PAGE and transferred to PVDF membrane. Western blot analysis was performed as described above.

**Screening of carbohydrate moiety using lectin-fluorescent staining**

Four FITC-labeled lectins with different carbohydrate specificity were used; concanavalin A (ConA) specific for high a-mannose-type and hybrid-type oligosaccharide, wheat germ agglutinin (WGA) specific to N-acetylated-glucosamine and sialic residues, peanut agglutinin (PNA) specific to galactose and N-acetylated-galactosamine, and Ulex europaeus agglutinin (UEA-1) specific to fucose (Fuco1-2Gal-R). Briefly, serum proteins from normal and lung cancer serum were first separated on 2-DE, then by transferred to PVDF membrane. The membranes were blocked for 2 h with 5% non-fat skim milk and 0.1% Tween-20 in PBS, followed by incubation with FITC-labeled lectins (a final concentration of approximately 20 µg/ml) at room temperature for 2 h. After washing three times with PBS-0.1% Tween-20, the membranes were scanned using a Typhoon 9200 laser scanner (GE Healthcare) with a fluorescent-wavelength at 526 nm.

**Results**

**2-DE of human serum samples**

Comparison of the differential protein expression profiles between normal healthy and NSCLC serum samples was performed by 2-DE analysis. Using the wide pH range of 3-10NL IPG strips, the 2-D gel patterns of normal and NSCLC serum samples showed the different protein profiles, particularly in the molecular weight range of 20 kDa and 30-55 kDa (Figure 1A). Since there was no significant difference between the highly acidic and basic areas, the narrow pH range 4-7L IPG strips were used to focus the different protein spots in the narrow pH range of 2-D gels. The different protein spots on the narrow pH range were distinctly elucidated, especially at the molecular weight range of 20 kDa (Figure 1B). There were two protein spots with approximate molecular weight at 18 kDa that were markedly changed with two-fold protein spot intensity in NSCLC serum (Figure 2A). After MALDI-TOF MS analysis, they were identified to be the haptoglobin alpha-2 chain (HAP2). The possibility-based scoring of the mass spectra of HAP2 isoforms revealed the high score of the mass database search, which indicated that these two spots were HAP2 (Table 1). These HAP2 isoforms in normal and lung cancer serum samples appeared at the same molecular weight but differ in pI values with values of 5.95 and 5.60 (for normal sample), and 5.90 and 5.65 (for cancer sample).
Two isoforms of HAP2 were also confirmed by LC-MS/MS and NH$_2$-terminal amino acid sequencing. LC-MS/MS data showed the matching protein of HAP2 with the similar peptide matching sequences in both isoforms, and the fifteen residues of NH$_2$-terminal amino acid sequences of HAP2 isoforms were V-D-S-G-N-D-V-T-D-I-A-D-D-G-C (Figure 2B). These sequences were used to search the matching protein on the ExPASy database using the BLAST program and the results identified these proteins as HAP2. In addition to 2-DE analysis, 2-D DIGE was also used to analyze the different protein expressions between normal and NSCLC serum samples, which were labeled with Cy3 (green) and Cy5 (red) dyes, respectively. 2-D DIGE results showed the distinctly different protein spots with different fluorescent colors (Figure 3) and the HAP2 isofrom spots were markedly up-regulated in NSCLC serum with the higher fluorescent intensity in red color, the same as the 2-DE result. Therefore, it could be confirmed that HAP2 isoforms were the up-regulated proteins in NSCLC serum.

Validation of HAP2 in human materials by western blot analysis

In general, the SDS-PAGE result showed that the protein
expression level of HAP2 in NSCLC serum samples was higher than the expression level of HAP2 in normal serum samples (Figure 4A). To confirm and validate the protein expression level of HAP2 in normal and NSCLC serum samples, the western blot analysis against anti-human haptoglobin was performed. The expression level of HAP2 in NSCLC serum samples was much higher than the expression level of HAP2 in normal serum samples (Figure 4B). A comparison of average protein band intensities of HAP2 expression level between normal and NSCLC serum samples from various NSCLC subtypes revealed that the high expression level of HAP2 was observed in adenocarcinoma, squamous carcinoma and unknown type of lung cancer, with the intensities of 3.90, 2.45 and 3.55-fold, respectively, the intensity of normal serum samples (Figure 4C). In addition, the protein expression levels of HAP2 in various human lung cancer materials, including serum, tissues, cell lines and cultured media of cultivated lung cancer cell lines, were validated (Figure 5A-D). Interestingly, the up-regulation of HAP2 was observed in the serum samples, while the HAP2 expression level in the lung tissues was variable. The HAP2 expression levels in 3 types of lung cancer cell lines were not observed, but it was observed in HepG2 cells. This was indicated that the up-regulated HAP2 has the specific expression only in human serum samples. To further verify the above observations, the identity of HAP2 in serum samples was confirmed by

Table 1: Protein identification of HAP2 by LC-MS/MS analysis.

| Spot No. | Acc. No. | Observed MW/pI | Theoretical MW/pI | Mowse score | % Seq. cov | Matching peptide sequences |
|----------|----------|----------------|------------------|-------------|------------|----------------------------|
| N-1 P00738 | 18000/5.95 | 41717/6.23 | 133 | 8 | TEGDGVYTLNDK LRTEDGVYTLNNEK TEGDGVYTLNNEK WINK |
| N-2 P00738 | 18000/5.60 | 41717/6.23 | 117 | 7 | YQCKNYK LRTEDGVYTLNNEK |
| L-1 P00738 | 18000/5.90 | 41717/6.23 | 259 | 12 | YQCKNYK NYYKLR TEGDGVYTLNDK |
| L-2 P00738 | 18000/5.65 | 41717/6.23 | 645 | 24 | YQCKNYK NYYKLR TEGDGVYTLNDK  |

Table 2: Protein sequence of identified HAP2 (Swiss-Prot accession no. P00738) and NH2-terminal amino acid sequence (underline).
co-immunoprecipitation, followed by western blotting. The result of HAP2 expression showed the up-regulation in NSCLC serum samples clearly, as compared to normal serum samples (Figure 5E).

**Detection of haptoglobin isoforms using different staining methods**

In order to investigate the PTMs of HAP2 isoforms, we used two fluorescent dye stains; Pro-Q® Emerald 488 glycoprotein gel stain and Pro-Q® Diamond phosphoprotein gel stain, to visualize the glycosylation and the phosphorylation of HAP2, respectively (Figure 6). From our results, the HAP2 isoforms in normal and NSCLC serum samples could be detected by both staining methods, in which the fluorescent intensity of HAP2 in the NSCLC serum samples was higher than that of the normal serum samples. Thus, HAP2 could be classified to be both glycoprotein and phosphoprotein. We suggest that HAP2 isoforms may have glycosylation and phosphorylation due to the high amounts of oligosaccharides and phosphates modified in the NSCLC serum samples, as compared to the normal serum samples.

**Carbohydrate specificity of hap2 by fluorescent-labeled lectin staining**

In order to detect the glycoprotein of HAP2 using the Pro-Q® Emerald 488 glycoprotein gel stain, we used fluorescent-labeled lectins to screen the presence of the specific carbohydrate moiety of HAP2 in normal and NSCLC serum samples. After the staining of 2-D gels with four types of FITC-labeled lectins, the HAP2 regions from NSCLC serum samples were apparently different compared to the HAP2 regions from normal serum samples (Figure 7). Interestingly,
The cutting 2-D gels of HAP2 region from normal serum; 4, immunoprecipitated haptoglobin in normal serum (A); lanes: 1-3, normal serum samples; 4-9, lung cancer serum samples. Human lung tissues (B); lanes: 1-4, normal lung tissues; 5-8, lung cancer tissues. Lung cancer cell lines (C); lanes: 1, NCI-H838 adenocarcinoma cell line; 2, SW900 squamous cell carcinoma cells; 3, NCI-H661 large cell carcinoma cells; 4, lung cancer serum sample (positive control). Western blot analysis of HAP2 in various human materials.

Figure 4: Validation of HAP2 in various human serum samples by western blotting against anti-human haptoglobin. (A) HAP2 regions of SYPRO® Ruby stained 1-D SDS PAGE gels from individual human serum patients. (B) Western blotting analysis of HAP2 in many human serum samples from healthy and NSCLC patients. Labels: N, normal serum samples (N4-N7, N9, N10-13); L, NSCLC serum samples (Adenocarcinoma (AC) – L1, L7, L10, L15, L19, L22, L23, L29; Squamous cell carcinoma (SQ) – L2, L5, L6, L8, L17; Unknown type of lung cancer (UN) – L4, L12, L18, L25, L26) and M, molecular weight markers are shown to the left. (C) Comparative protein band intensities of HAP2 expression level in normal and NSCLC serum samples.

Figure 5: Western blot analysis of HAP2 in various human materials. The numbers of samples were obtained from different sources and donors. Human serum samples (A); lanes: 1-3, normal serum samples; 4-9, lung cancer serum samples. Human lung tissues (B); lanes: 1-3, normal lung tissues; 4-9, lung cancer tissues. Lung cancer cell lines (C); lanes: 1, NCI-H838 adenocarcinoma cells; 2, SW900 squamous cell carcinoma cells; 3, NCI-H661 large cell carcinoma cells; 4, lung cancer serum samples (positive control); 5, HepG2 hepatocellular carcinoma cells. Cultured cell medium samples (D); lanes: 1, cultured medium of adenocarcinoma cells containing 10% fetal bovine serum (FBS); 2, cultured medium containing 5% FBS; 3, serum free medium; 4, lung cancer serum sample (positive control). Western blot analysis of co-immunoprecipitated haptoglobin in normal and lung cancer serum samples (E); lanes: 1, normal serum; 2, lung cancer serum; 3, immunoprecipitated haptoglobin in normal serum; 4, immunoprecipitated haptoglobin in lung cancer serum.

Figure 6: Detection of glycosylated and phosphorylated HAP2 isoforms using Pro-Q® dye stains. The cutting 2-D gels of HAP2 region from normal (A) and NSCLC (B) serum samples were stained using Pro-Q® Emerald glycoprotein stain (A1, B1) for glycoprotein detection and Pro-Q® Diamond phosphoprotein gel stain (A2, B2) for phosphoprotein detection.

The HAP2 isoforms in NSCLC serum samples gave a strongly positive fluorescent signal against FITC-labeled WGA rather than FITC-labeled ConA and FITC-labeled PNA, but none were observed with FITC-labeled UE1a. Due to the specificity of WGA on core sialylation and N-acetyl glucosamine (GlcNAc), the appearance of the WGA bound HAP2 indicated that a high expression level of sialylation and/or GlcNAc in HAP2 may be associated with the NSCLC development.

Detection of Sialyl Lewis x in HAP2

To further detect the expression of sialyl Lewis x in human serum samples, we used the co-immunoprecipitation with anti-sialyl Lewis x monoclonal antibody and followed by SDS-PAGE analysis. The SDS-PAGE profile showed a high sialyl Lewis x expression on HAP2 in the crude serum sample and the co-immunoprecipitated sample of NSCLC serum, while its expression was rarely observed in those of normal serum (Figure 8). Our result suggested that the expression of sialyl Lewis x carbohydrate antigen in NSCLC serum sample might cause a change in the glycosylation of HAP2 protein in NSCLC serum.

Discussion

Presently, many human diseases need more diagnostic tools to aid in the early evaluation of biomarkers for understanding their biological mechanisms. Proteomics approaches have been challenged to find out the protein markers and to study the change of the quantitative
display of proteins in serum and other biological materials [10-13].

In this study, we reported the proteomic analysis of potential protein markers in NSCLC lung cancer serum using gel-based proteomic tools, including 2-DE, 2-D DIGE and MS. We found that HAP2 was markedly up-regulated in NSCLC serum samples and may play a critical role in NSCLC development. Usually, haptoglobin is among the most abundant glycoproteins generally secreted by the liver and is composed of two different polypeptides (α- and β-chains) whose α and β chains are covalently conjugated via disulfide bonds [14-16]. According to the 2-DE result, the molecular weight of HAP2 was observed at 18,000 Da, but the theoretical molecular weight of matched HAP2 from SwissProt accession number P00738 was 41,717 Da. Comparing to the matching peptide sequences and NH-terminal amino acid sequences, those sequences were matched to the haptoglobin alpha chain while there were no matches for the haptoglobin beta chain. The observed molecular weight of HAP2 was the same as the haptoglobin alpha chain. Thus, it was clear that the identified HAP2 in both normal and NSCLC serum samples was reliable and proven. In addition, it is well known that the functional properties of haptoglobin are involved in binding free hemoglobin, protection against free radicals, inhibition of nitric oxide, inhibition of prostaglandin synthesis, bacteriostatic effect, angiogenesis, antibody-like properties and interactions with leukocytes [17]. The high expression level of haptoglobin in serum has been found in many cancers such as breast cancer [18], hepatocellular carcinoma [19], ovarian cancer [14], pancreatic cancer [20], and lung cancer [15, 21, 22]. Although a few studies of haptoglobin have been reported in individual types of lung cancer, the expression and validation of haptoglobin in all types of lung cancer and various human materials has never been reported. Therefore, it is very interesting to investigate the expression level of haptoglobin in NSCLC serum samples and various human materials and through the determination of the carbohydrate specificity of HAP2.

Determination of the individual human serum samples is necessary to examine whether differences observed in most of the histological types of lung cancer and because there are a small amount of differential individuals within the lung cancer group [23]. Validation of the biomarkers is an important result of proteomic analysis for confirmation of the cancer marker before use in clinical applications. In this study, we have validated the expression level of HAP2 in the individual human serum specimen from various histological types of lung cancer by comparative 2-DE and western blot analyses. Both analyses provided the same results of up-regulation of HAP2 in the individual NSCLC serum sample. The western blot analysis also demonstrated the higher expression level of HAP2 in adenocarcinoma than squamous cell carcinoma and unknown type lung cancer. This indicates that the HAP2 expression level showed the highest specificity in adenocarcinoma lung cancer. Although the unknown unknown type of lung cancer serum samples that could not be identified the type of lung cancer also provided the high expression level of HAP2, the expression level of HAP2 in NSCLC serum could possibly be used for preliminary diagnosis of lung cancer. In addition, the expression of HAP2 was validated in various human materials such as serum, lung cancer tissues, lung cancer cells, and cultured cell media. The HAP2 expression could be detected clearly in human serum with the higher expression in NSCLC serum compared to normal serum. There was no significant increase in the relative amount of HAP2 in lung cancer tissues and none observed in the primary normal cells and three types of NSCLC cell lines. Due to the synthesis of haptoglobin by the liver cells in response to a variety of stimuli and secretion into the bloodstream [17], we proposed that the HAP2 may spread to other organells; for example, HAP2 in the cell lines may be secreted into the cultured cell media. After we determined the HAP2 expression in the cultured cell media in the absence and presence of fetal bovine serum (FBS), no HAP2 was observed. This indicated that HAP2 is neither produced from lung cancer tissues and/or cells nor secreted to the biofluid. Therefore, the high expression level of HAP2 in NSCLC has the specificity in the human serum samples. Moreover, the HAP2 expression was observed in the HepG2 cell line. We suggest that the HAP2 is not produced from lung tissues and/or cells, but it is synthesized by the liver, especially hepatocytes, and secreted to the serum or plasma [21, 24].

Figure 7: Detection of carbohydrate moiety of HAP2 isoforms in normal (A) and NSCLC (B) serum samples using FITC-labeled lectins staining. The serum proteins from normal and NSCLC serum samples were separated on 2-DE and followed by transferred onto PVDF membrane. The 2-D gels were stained with four FITC-labeled lectins. Labels: 1, FITC-labeled WGA; 2, FITC-labeled ConA; 3, FITC-labeled PNA; 4, FITC-labeled UEA-I.

Figure 8: Co-immunoprecipitation of sialylated carbohydrate antigen in HAP2 from human serum samples with monoclonal anti-sialyl Lewis x. The immunoprecipitated sialyl Lewis x profiles were resolved by SDS-PAGE and the gel was stained with SYPRO® Ruby gel stain.
Changes in protein quantity and isoforms may be caused by PTMs such as glycosylation and phosphorylation [25]. Currently, the specificity of staining methods has been developed for use in the proteomics platform, in which the patterns of general proteins, glycoproteins and phosphoproteins can be visualized using various protein staining methods [26,27]. The Pro-Q® dye stains are one of the high sensitivity staining methods and are used to detect the glycoproteins and phosphoproteins within the nanogram range of proteins per band. Pro-Q® Emerald 488 dye reacts with periodateoxidized carbohydrate groups, creating a bright green-fluorescent signal on glycoprotein [28], while Pro-Q® Diamond dye is used to detect phosphate groups attached to tyrosine, serine or threonine residues [29]. According to our result of differential expression of HAP2 isoforms, the 2-DE combined with fluorescence Pro-Q® dye stains has been proven to be an effective method for detecting glycosylation and phosphorylation of HAP2 isoforms. The HAP2 isoforms of NSCLC serum showed higher fluorescent spot intensity than that of normal serum in both dye stains, especially by Pro-Q® Diamond phosphoprotein dye stain. We suggest that the HAP2 isoforms in NSCLC serum may be caused by glycosylation and phosphorylation. Although the glycosylation of haptoglobin has been reported in various cancers [18,20,30], especially in lung cancer that contains the fucosylation of the haptoglobin β-subunit [31-33], there is no description about the intrinsic glycosylation changes of the haptoglobin α-subunit content as well as the phosphorylation of HAP2 isoforms in lung cancer. On the other hand, we also investigated the carbohydrate specificity of HAP2 using FITC-labeled lectin staining. According to the preferential binding of lectin on carbohydrate moiety, the carbohydrate specificities of HAP2 isoforms in normal and NSCLC serum samples were detected, and FITC-WGA lectin showed the best affinity for binding with HAP2. This indicated that HAP2 contained a high amount of N-acetyl glucosamine and/or sialic acid. The slight detection of HAP2 in NSCLC serum using ConA and PNA lectins also indicated the low contents of glucose/mannose and galactose/N-acetyl galactosamine. Moreover, the high expression of sialylated carbohydrate antigen has been reported to correlate with distant metastasis and survival in lung cancer patients [34-36]. Thus, the sialyl Lewis x was also investigated in the normal and lung cancer serum samples by co-immunoprecipitation technique. This approach enabled us to detect the specific sialyl Lewis x on HAP2 in lung cancer serum samples. Our results suggest that the increase of the sialylation of HAP2 may lead to changes in the core structure of glycans or glycosylation pattern corresponding to the stage of lung cancer and lung cancer development. Furthermore, the extent of sialylation may be a useful marker for the evaluation of the glycosylation status of serum glycoproteins in lung cancer patients. Nevertheless, this information may be used to study carbohydrate structural changes of differentially expressed haptoglobin isoforms that will be characterized in further studies as well as through the study of functional mechanism of lung cancer.

In conclusion, we used proteomic approaches to investigate the HAP2 in both normal and NSCLC serum samples, in which the HAP2 was significantly up-regulated in NSCLC serum. The detection technologies of Pro-Q glycoprotein and phosphoprotein stains and FITC-labeled lectin stains provided the visualization of certain modified protein classes or PTMs between normal and NSCLC serum samples and also showed that the high expression of HAP2 isoforms in NSCLC serum was caused by glycosylation and phosphorylation, which may correspond to the metastasis of the tumor and/or the stage of cancer progression. In addition, the validation of HAP2 in various human materials provided two pieces of evidence: (i) the expression of HAP2 has the specificity in human serum samples only; and (ii) the HAP2 is not produced from lung tissues and/or cells, but it may be secreted from the liver. Moreover, HAP2 may become the potential biomarker in NSCLC serum that is useful for further diagnostic and therapeutic applications. However, the further investigations of the oligosaccharide composition in HAP2 and its phosphorylation corresponding to the modification change in lung cancer are necessary to a more complete understanding, clarity, and can be achieved through the study of biological mechanisms of lung cancer disease.

Acknowledgements

This report is part of Royal Golden Jubilee Ph.D. project of Ms. Supawadee Sriyam supported by the Thailand Research Fund (TRF), Thailand. We gratefully acknowledge the Lampang Regional Cancer Center, Thailand for providing serum samples and the System Biology Laboratory (SBL), Institute of Biological Chemistry, Academia Sinica, Taiwan for general support and assistance in this research. We thank the Core Facilities for Proteomics and Structural Biology Research, Academia Sinica, Taiwan for proteomics facilities, and the Graduate School, Chiang Mai University, Thailand for accomplishing this project.

References

1. Lam WK (2005) Lung cancer in Asian women-the environment and genes. Respir Res 10: 408-417.
2. Srirugun H, Sortiproon S, Martin N, Wlangsnon N, Voitplnu V, et al. (2005) Cancer incidence in Thailand, 1995-1997. Asian Pac J Cancer Prev 6: 276-281.
3. Liaw YP, Huang YC, Lien GW (2005) Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health 6: 22.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
5. Fry WA, Phillips JL, Mench LR (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86: 1867-1876.
6. Jacobs JM, Adkins NJ, Qian WJ, Liu T, Shen Y, et al. (2005) Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 4: 1073-1085.
7. Hu S, Loo JA, Wong DT (2006) Human body fluid proteome analysis. Proteomics 6: 6326-6353.
8. Okano T, Kondo T, Kakisaka T, Fuji K, Yamada M, et al. (2006) Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 6: 3938-3948.
9. Steel LF, Shumpert D, Trotter M, Seelhorzer SH, Evans AA, et al. (2003) A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3: 601-609.
10. Anderson NL, Polanski M, Pieper R, Gattin T, Tinumalai RS, et al. (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326.
11. Pieper R, Gattin CL, Makusky AJ, Russo PS, Schatz CR, et al. (2003) The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 different proteins. Proteomics 3: 1345-1364.
12. Purohit S, Podolsky R, Schatz D, Muir A, Hopkins D, et al. (2006) Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics 6: 6405-6415.
13. Ménard C, Johann D, Lowenthal M, Muanza T, Sproull M, et al. (2006) Discovering clinical biomarkers of ionizing radiation exposure with serum proteomics analysis. Cancer Res 66: 1844-1850.
14. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, et al. (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911.
15. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, et al. (2005) Differential proteomic serum pattern of low molecular weight proteins.
expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol 5: 31-38.

16. Pavón EJ, Muñoz P, Lario A, Longobardo V, Carrascal M, et al. (2006) Proteomic analysis of plasma from patients with systemic lupus erythematosus: Increased presence of haptoglobin alpha2 polypeptide chains over the alpha 1 isoforms. Proteomics 6: S282-S292.

17. Langlois MR, Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600.

18. Awadallah SM, Atoum MF (2004) Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta 341: 17-21.

19. Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, et al. (2006) Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 5: 2691-2700.

20. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, et al. (2006) Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 118: 2803-2808.

21. Bharti A, Ma PC, Maulik G, Singh R, Khan E, et al. (2004) Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24: 1031-1038.

22. Dowling P, O’Driscoll L, Meleady P, Henry M, Roy S, et al. (2007) 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 28: 4302-4310.

23. Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32: 169-176.

24. Theilgaard-Mönch K, Jacobsen LC, Nielsen MJ, Rasmussen T, Uldby L, et al. (2006) Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood 108: 353-361.

25. Thompson S, Turner GA (1987) Elevated levels of abnormally-fucosylated haptoglobin in cancer sera. Br J Cancer 56: 605-610.

26. Wu J, Lenchik NJ, Pabst MJ, Solomon SS, Shull J, et al. (2005) Functional characterization of two-dimensional gel-separated proteins using sequential staining. Electrophoresis 26: 225-237.

27. Ge Y, Rajkumar L, Guzman RC, Nandi S, Patton WF, et al. (2004) Multiplexed fluorescence detection of phosphorylation, glycosylation, and total protein in the proteomic analysis of breast cancer refractoriness. Proteomics 4: 3464-3467.

28. Hart C, Schulenberg B, Steinberg TH, Leung WY, Patton WF (2003) Detection of glycoproteins in polyacrylamide gels and on electrophlots using Pro-Q Emerald 488 dye, a fluorescent periodate Schiff-base stain. Electrophoresis 24: 588-598.

29. Steinberg TH, Agnew BJ, Gee KR, Leung WY, Goodman T, et al. (2003) Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics 3: 1128-1144.

30. Turner GA (1995) Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol 376: 231-238.

31. Thompson S, Dargan E, Turner GA (1992) Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 66: 43-48.

32. Mann AC, Record CO, Self CH, Turner GA (1994) Monosaccharide composition of haptoglobin in liver diseases and alcohol abuse: large changes in glycosylation associated with alcoholic liver disease. Clin Chim Acta 227: 69-78.

33. Thompson S, Kelly CA, Griffiths ID, Turner GA (1989) Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease. Clin Chim Acta 184: 251-258.

34. Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K (2002) Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis. Thorax 57: 263-266.

35. Mizuguchi S, Inoue K, Iwata T, Nishida T, Izumi N, et al. (2006) High serum concentrations of Sialyl Lewisx predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol 13: 1010-1018.

36. Fukuoka K, Narita N, Sajo N (1998) Increased expression of sialyl Lewisx antigen is associated with distant metastasis in lung cancer patients: immunohistochemical study on bronchofiberscopic biopsy specimens. Lung Cancer 20: 109-116.